Literature DB >> 28427704

Comparison of brain and spinal cord magnetic resonance imaging features in neuromyelitis optica spectrum disorders patients with or without aquaporin-4 antibody.

Moli Fan1, Ying Fu1, Lei Su1, Yi Shen1, Kristofer Wood2, Li Yang1, Yaou Liu3, Fu-Dong Shi4.   

Abstract

BACKGROUND: The spinal cord and brain measurements are rarely investigated in neuromyelitis optica (NMO) patients with and without antibodies to aquaporin-4 (AQP4), directly compared to multiple sclerosis (MS) patients.
OBJECTIVES: To investigate magnetic resonance imaging (MRI) features of both brain and spinal cord in NMO patients with and without antibodies to AQP4, compared with MS patients and healthy controls (HC).
METHODS: We recruited 55 NMO including 30 AQP4 (+) and 25 AQP4 (-), 25 MS and 25 HC. Brain and spinal cord MRIs were obtained for each participant. Brain lesions (BL), whole brain and deep grey matter volumes (DGMV), white matter diffusion metrics and spinal cord lesions were measured and compared among groups.
RESULTS: The incidence of BL was lower in the AQP4 (+) group than in the AQP4 (-) and MS groups (p<0.05). In the AQP4 (+) group, there was a lower incidence of infratentorial lesions (ITL) and higher spinal cord lesions length than in the MS group (p<0.05). The thalamic and hippocampal volumes were smaller in the AQP4 (-) group and MS group than in the HC group (p<0.05).
CONCLUSIONS: The NMO patients with AQP4 (-) showed higher prevalence of BL, ITL, and similar spinal cord lesion length, compared to AQP4 (+), and demonstrated deep grey matter atrophy, suggesting an intermediate phenotype between that of typical MS and NMO.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Aquaporin 4; Brain; MRI features; Neuromyelitis optica; Spinal cord

Mesh:

Substances:

Year:  2017        PMID: 28427704     DOI: 10.1016/j.msard.2017.02.003

Source DB:  PubMed          Journal:  Mult Scler Relat Disord        ISSN: 2211-0348            Impact factor:   4.339


  7 in total

1.  Radiomics in multiple sclerosis and neuromyelitis optica spectrum disorder.

Authors:  Yaou Liu; Di Dong; Liwen Zhang; Yali Zang; Yunyun Duan; Xiaolu Qiu; Jing Huang; Huiqing Dong; Frederik Barkhof; Chaoen Hu; Mengjie Fang; Jie Tian; Kuncheng Li
Journal:  Eur Radiol       Date:  2019-02-15       Impact factor: 5.315

2.  A Comparative Analysis of Clinical and Imaging Features of Aquaporin 4 (AQP4) Antibody Positive, Myelin Oligodendrocyte Glycoprotein (MOG) Antibody Positive and Double Seronegative Subtypes of Neuro Myelitis Optica Spectrum Disorder (NMOSD).

Authors:  Salil Gupta; Varun Rehani; Pawan Dhull; Manoj Somasekharan; Amit Sreen
Journal:  Ann Indian Acad Neurol       Date:  2022-02-09       Impact factor: 1.714

3.  Comparison of spontaneous brain activity revealed by regional homogeneity in AQP4-IgG neuromyelitis optica-optic neuritis versus MOG-IgG optic neuritis patients: a resting-state functional MRI study.

Authors:  Junqing Wang; Yuan Tian; Yi Shao; Hui Feng; Limin Qin; Weiwei Xu; Hongjuan Liu; Quangang Xu; Shihui Wei; Lin Ma
Journal:  Neuropsychiatr Dis Treat       Date:  2017-10-24       Impact factor: 2.570

4.  Non-lesional cerebellar damage in patients with clinically isolated syndrome: DTI measures predict early conversion into clinically definite multiple sclerosis.

Authors:  Alexa V Kugler; Michael Deppe
Journal:  Neuroimage Clin       Date:  2018-04-24       Impact factor: 4.881

Review 5.  Diagnosis and Treatment of NMO Spectrum Disorder and MOG-Encephalomyelitis.

Authors:  Nadja Borisow; Masahiro Mori; Satoshi Kuwabara; Michael Scheel; Friedemann Paul
Journal:  Front Neurol       Date:  2018-10-23       Impact factor: 4.003

6.  Deep Gray Matter Iron Content in Neuromyelitis Optica and Multiple Sclerosis.

Authors:  Adam Pudlac; Andrea Burgetova; Petr Dusek; Petra Nytrova; Manuela Vaneckova; Dana Horakova; Jan Krasensky; Lukas Lambert
Journal:  Biomed Res Int       Date:  2020-05-19       Impact factor: 3.411

Review 7.  Cognitive impairment in NMOSD-More questions than answers.

Authors:  Dominika Czarnecka; Magdalena Oset; Iwona Karlińska; Mariusz Stasiołek
Journal:  Brain Behav       Date:  2020-10-06       Impact factor: 2.708

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.